A new patch just created will one day monitor a person’s health using minuscule sweat samples. The patch is being developed by Biotex, a consortium of European research institutes and companies, including the Swiss Centre for Electronics and Microtechnology (CSEM).

Most clothing designed for health monitoring focuses on physiological measurements, such as body temperature and heart rate. This is one of the first attempts to continuously analyze biochemical signals using clothing. The team employed a novel approach for monitoring: a combination of hydrophilic and hydrophobic yarns woven together to channel the sweat to the sensors. By utilizing natural attraction and repulsion actions to move the sweat, the method also circumvents the need for additional power sources, which would add bulk to such a device and make it less convenient for everyday use.

Once the fabric has directed a few milliliters of sweat into the patch, the sensors determine the amount of potassium, chloride, or sodium present. Measuring these electrolytes can provide insight into a person’s metabolism. By comparing the electrolyte amounts to reference measurements, such a system could indicate if the user is overexerting herself or stressed, says Jean Luprano, project coordinator at the CSEM.

Once the tiny reservoirs are full of sweat, the user throws away the chemical part of the patch, which is about 5 to 10 square inches. The patch-embedded band or shirt can be washed, and the monitoring electronics reused.  This sounds like sci-fi but it reminds me if the new terminator tv show where the robot can diagnose your physical health by tasting your sweat.

Medtronic on has received federal approval to sell its drug-coated stent, the first to hit the U.S. market since safety concerns sank their popularity two years ago.  The Food and Drug Administration said it cleared the company’s Endeavor stent for use in patients with clogged arteries. Medtronic said it expects to ship 100,000 units to hospitals in February.

Endeavor is one of a new generation of stents the industry hopes can rejuvenate U.S. demand for the drug-oozing devices, sales of which plummeted to $2 billion last year, down from a peak of $3.1 billion in 2005.

Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque. They became one of the most lucrative medical devices in modern history after companies began adding drug coatings to stents in 2003 to prevent blood clotting.

An estimated 6 million people worldwide have had one implanted.  Hopefully this new one is going to be problem free.